Nyzol (Olanzapine)

Olanzapine, the active ingredient in Nyzol, is a atypical antipsychotic presented as an oral tablet for oral use. It is indicated for the management of schizophrenia, bipolar I disorder and acute manic episodes in adult patients. GNH USA supplies Nyzol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olanzapine is an atypical antipsychotic that modulates dopamine and serotonin pathways in several psychiatric conditions. - Schizophrenia: helps reduce psychotic symptoms such as delusions, hallucinations and thought disorder. - Bipolar I disorder: stabilises mood and prevents recurrence of depressive or manic phases. - Manic episodes: rapidly controls elevated mood, hyperactivity and irritability during acute mania.

Olanzapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Weight gain: increased appetite leading to noticeable weight increase. - Sedation: drowsiness or feeling unusually tired. - Dry mouth: reduced salivation causing discomfort. - Constipation: slowed gastrointestinal motility. - Dizziness: light‑headed sensation, especially when standing. - Increased appetite: heightened desire for food.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and muscle rigidity. - Agranulocytosis: severe drop in white blood cells, increasing infection risk. - Hyperglycaemia: elevated blood sugar that may precipitate diabetes. - Seizures: occurrence of convulsive episodes. - Tardive dyskinesia: involuntary, repetitive movements, often of the face. - Myocarditis: inflammation of the heart muscle, potentially fatal.

Before initiating therapy, clinicians should assess several safety parameters. - Metabolic monitoring: regularly check weight, glucose and lipid levels. - Cardiovascular assessment: evaluate blood pressure and heart rate, especially in patients with pre‑existing disease. - Seizure history: use with caution in individuals with a history of seizures. - Elderly patients: avoid use in dementia‑related psychosis due to increased mortality risk. - Discontinuation: taper gradually to minimise withdrawal or relapse. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Olanzapine can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP1A2 inhibitors (e.g., fluvoxamine): may raise olanzapine plasma levels. - Potent CYP3A4 inhibitors (e.g., ketoconazole): increase risk of toxicity. - CNS depressants (e.g., alcohol, benzodiazepines): can enhance sedation and respiratory depression.

Moderate Interactions (Monitor Closely):\n- Antihypertensives: additive orthostatic hypotension may occur. - Antidiabetic agents: olanzapine‑induced hyperglycaemia may require dose adjustment. - Smoking: induces CYP1A2, potentially lowering olanzapine concentrations.